Table of Contents Author Guidelines Submit a Manuscript
International Journal of Cell Biology
Volume 2010, Article ID 818497, 10 pages
http://dx.doi.org/10.1155/2010/818497
Research Article

Inhibition by Anandamide of 6-Hydroxydopamine-Induced Cell Death in PC12 Cells

1School of Natural Sciences, National University of Ireland, Galway, Ireland
2School of Medicine, National University of Ireland, Galway, Ireland

Received 30 July 2009; Revised 22 October 2009; Accepted 10 November 2009

Academic Editor: Osamu Hori

Copyright © 2010 Katarzyna Mnich et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Ševčík and K. Mašek, “Potential role of cannabinoids in Parkinson's disease,” Drugs and Aging, vol. 16, no. 6, pp. 391–395, 2000. View at Google Scholar · View at Scopus
  2. J. Romero, I. Lastres-Becker, R. de Miguel, F. Berrendero, J. A. Ramos, and J. Fernández-Ruiz, “The endogenous cannabinoid system and the basal ganglia: biochemical, pharmacological, and therapeutic aspects,” Pharmacology and Therapeutics, vol. 95, no. 2, pp. 137–152, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. J. M. Brotchie, “CB1 cannabinoid receptor signalling in Parkinson's disease,” Current Opinion in Pharmacology, vol. 3, no. 1, pp. 54–61, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Fernández-Ruiz, J. Romero, G. Velasco, R. M. Tolón, J. A. Ramos, and M. Guzmán, “Cannabinoid CB2 receptor: a new target for controlling neural cell survival?” Trends in Pharmacological Sciences, vol. 28, no. 1, pp. 39–45, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Jimenez-Del-Rio, A. Daza-Restrepo, and C. Velez-Pardo, “The cannabinoid CP55,940 prolongs survival and improves locomotor activity in Drosophila melanogaster against paraquat: implications in Parkinson's disease,” Neuroscience Research, vol. 61, no. 4, pp. 404–411, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. W. A. Devane, L. Hanus, A. Breuer et al., “Isolation and structure of a brain constituent that binds to the cannabinoid receptor,” Science, vol. 258, no. 5090, pp. 1946–1949, 1992. View at Google Scholar · View at Scopus
  7. E. Fride and R. Mechoulam, “Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent,” European Journal of Pharmacology, vol. 231, no. 2, pp. 313–314, 1993. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Smart, M. J. Gunthorpe, J. C. Jerman et al., “The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1),” British Journal of Pharmacology, vol. 129, no. 2, pp. 227–230, 2000. View at Google Scholar · View at Scopus
  9. D. Matas, A. Juknat, M. Pietr, Y. Klin, and Z. Vogel, “Anandamide protects from low serum-induced apoptosis via its degradation to ethanolamine,” Journal of Biological Chemistry, vol. 282, no. 11, pp. 7885–7892, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Shouman, R. H. Fontaine, O. Baud et al., “Endocannabinoids potently protect the newborn brain against AMPA-kainate receptor-mediated excitotoxic damage,” British Journal of Pharmacology, vol. 148, no. 4, pp. 442–451, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. A. D. Sinor, S. M. Irvin, and D. A. Greenberg, “Endocannabinoids protect cerebral cortical neurons from in vitro ischemia in rats,” Neuroscience Letters, vol. 278, no. 3, pp. 157–160, 2000. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Schomacher, H. D. Müller, C. Sommer, S. Schwab, and W.-R. Schäbitz, “Endocannabinoids mediate neuroprotection after transient focal cerebral ischemia,” Brain Research, vol. 1240, pp. 213–220, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Contassot, R. Wilmotte, M. Tenan et al., “Arachidonylethanolamide induces apoptosis of human glioma cells through vanilloid receptor-1,” Journal of Neuropathology and Experimental Neurology, vol. 63, no. 9, pp. 956–963, 2004. View at Google Scholar · View at Scopus
  14. M. Maccarrone, T. Lorenzon, M. Bari, G. Melino, and A. Finazzi-Agro, “Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors,” Journal of Biological Chemistry, vol. 275, no. 41, pp. 31938–31945, 2000. View at Google Scholar · View at Scopus
  15. W. B. Veldhuis, M. van der Stelt, M. W. Wadman et al., “Neuroprotection by the endogenous cannabinoid anandamide and arvanil against in vivo excitotoxicity in the rat: role of vanilloid receptors and lipoxygenases,” Journal of Neuroscience, vol. 23, no. 10, pp. 4127–4133, 2003. View at Google Scholar · View at Scopus
  16. H. Thoenen and J. P. Tranzer, “Chemical sympathectomy by selective destruction of adrenergic nerve endings with 6-hydroxydopamine,” Naunyn-Schmiedebergs Archiv für Pharmakologie und Experimentelle Pathologie, vol. 261, no. 3, pp. 271–288, 1968. View at Publisher · View at Google Scholar · View at Scopus
  17. D. Blum, S. Torch, N. Lambeng et al., “Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease,” Progress in Neurobiology, vol. 65, no. 2, pp. 135–172, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Lotharius, L. L. Dugan, and K. L. O'Malley, “Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons,” Journal of Neuroscience, vol. 19, no. 4, pp. 1284–1293, 1999. View at Google Scholar · View at Scopus
  19. B. S. Han, H.-S. Hong, W.-S. Choi, G. J. Markelonis, T. H. Oh, and Y. J. Oh, “Caspase-dependent and -independent cell death pathways in primary cultures of mesencephalic dopaminergic neurons after neurotoxin treatment,” Journal of Neuroscience, vol. 23, no. 12, pp. 5069–5078, 2003. View at Google Scholar · View at Scopus
  20. W.-S. Choi, S.-Y. Yoon, T. H. Oh, E.-J. Choi, K. L. O'Malley, and Y. J. Oh, “Two distinct mechanisms are involved in 6-hydroxydopamine- and MPP+-induced dopaminergic neuronal cell death: role of caspases, ROS, and JNK,” Journal of Neuroscience Research, vol. 57, no. 1, pp. 86–94, 1999. View at Publisher · View at Google Scholar · View at Scopus
  21. G. Walkinshaw and C. M. Waters, “Neurotoxin-induced cell death in neuronal PC12 cells is mediated by induction of apoptosis,” Neuroscience, vol. 63, no. 4, pp. 975–987, 1994. View at Publisher · View at Google Scholar · View at Scopus
  22. A. M. Gorman, E. Szegezdi, D. J. Quigney, and A. Samali, “Hsp27 inhibits 6-hydroxydopamine-induced cytochrome c release and apoptosis in PC12 cells,” Biochemical and Biophysical Research Communications, vol. 327, no. 3, pp. 801–810, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. T. Mosmann, “Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays,” Journal of Immunological Methods, vol. 65, no. 1-2, pp. 55–63, 1983. View at Google Scholar · View at Scopus
  24. D. W. Nicholson, A. Ali, N. A. Thornberry et al., “Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis,” Nature, vol. 376, no. 6535, pp. 37–43, 1995. View at Google Scholar · View at Scopus
  25. A. M. Gorman, U. A. Hirt, B. Zhivotovsky, S. Orrenius, and S. Ceccatelli, “Application of a fluorometric assay to detect caspase activity in thymus tissue undergoing apoptosis in vivo,” Journal of Immunological Methods, vol. 226, no. 1-2, pp. 43–48, 1999. View at Publisher · View at Google Scholar · View at Scopus
  26. K. P. Sarker and I. Maruyama, “Anandamide induces cell death independently of cannabinoid receptors or vanilloid receptor 1: possible involvement of lipid rafts,” Cellular and Molecular Life Sciences, vol. 60, no. 6, pp. 1200–1208, 2003. View at Google Scholar · View at Scopus
  27. A. Someya, K. Kunieda, N. Akiyama, T. Hirabayashi, S. Horie, and T. Murayama, “Expression of vanilloid VR1 receptor in PC12 cells,” Neurochemistry International, vol. 45, no. 7, pp. 1005–1010, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. I. Lastres-Becker, F. Molina-Holgado, J. A. Ramos, R. Mechoulam, and J. Fernández-Ruiz, “Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease,” Neurobiology of Disease, vol. 19, no. 1-2, pp. 96–107, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. Y. Glinka, M. Gassen, and M. B. H. Youdim, “Mechanism of 6-hydroxydopamine neurotoxicity,” Journal of Neural Transmission, Supplement, vol. 50, pp. 55–66, 1997. View at Google Scholar · View at Scopus
  30. J. E. Cavanaugh, J. D. Jaumotte, J. M. Lakoski, and M. J. Zigmond, “Neuroprotective role of ERK1/2 and ERK5 in a dopaminergic cell line under basal conditions and in response to oxidative stress,” Journal of Neuroscience Research, vol. 84, no. 6, pp. 1367–1375, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. Z. Lu and S. Xu, “ERK1/2 MAP kinases in cell survival and apoptosis,” IUBMB Life, vol. 58, no. 11, pp. 621–631, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. E. Szegezdi, K. Reed Herbert, E. T. Kavanagh, A. Samali, and A. M. Gorman, “Nerve growth factor blocks thapsigargin-induced apoptosis at the level of the mitochondrion viaregulation of Bim,” Journal of Cellular and Molecular Medicine, vol. 12, no. 6A, pp. 2482–2496, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Eminel, A. Klettnert, L. Roemer, T. Herdegen, and V. Waetzig, “JNK2 translocates to the mitochondria and mediates cytochrome c release in PC12 cells in response to 6-hydroxydopamine,” Journal of Biological Chemistry, vol. 279, no. 53, pp. 55385–55392, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. B. Chetsawang, P. Govitrapong, and M. Ebadi, “The neuroprotective effect of melatonin against the induction of c-Jun phosphorylation by 6-hydroxydopamine on SK-N-SH cells,” Neuroscience Letters, vol. 371, no. 2-3, pp. 205–208, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. H. J. Lee, Y. H. Noh, D. Y. Lee et al., “Baicalein attenuates 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells,” European Journal of Cell Biology, vol. 84, no. 11, pp. 897–905, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. L.-L. Tian, Z. Zhou, Q. Zhang et al., “Protective effect of (±) isoborneol against 6-OHDA-induced apoptosis in SH-SY5Y cells,” Cellular Physiology and Biochemistry, vol. 20, no. 6, pp. 1019–1032, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Chao, M.-S. Yu, Y.-S. Ho, M. Wang, and R. C.-C. Chang, “Dietary oxyresveratrol prevents parkinsonian mimetic 6-hydroxydopamine neurotoxicity,” Free Radical Biology and Medicine, vol. 45, no. 7, pp. 1019–1026, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. M. A. Bogoyevitch and B. Kobe, “Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases,” Microbiology and Molecular Biology Reviews, vol. 70, no. 4, pp. 1061–1095, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. S. C. Biswas and L. A. Greene, “Nerve growth factor (NGF) down-regulates the Bcl-2 homology 3 (BH3) domain-only protein Bim and suppresses its proapoptotic activity by phosphorylation,” Journal of Biological Chemistry, vol. 277, no. 51, pp. 49511–49516, 2002. View at Publisher · View at Google Scholar · View at Scopus
  40. E. B. E. Becker, J. Howell, Y. Kodama, P. A. Barker, and A. Bonni, “Characterization of the c-Jun N-terminal kinase-BimEL signaling pathway in neuronal apoptosis,” Journal of Neuroscience, vol. 24, no. 40, pp. 8762–8770, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Guzmán, C. Sánchez, and I. Galve-Roperh, “Control of the cell survival/death decision by cannabinoids,” Journal of Molecular Medicine, vol. 78, no. 11, pp. 613–625, 2001. View at Publisher · View at Google Scholar · View at Scopus
  42. D. Rueda, B. Navarro, A. Martínez-Serrano, M. Guzmán, and I. Galve-Roperh, “The endocannabinoid anandamide inhibits neuronal progenitor cell differentiation through attenuation of the Rap1/B-Raf/ERK pathway,” Journal of Biological Chemistry, vol. 277, no. 48, pp. 46645–46650, 2002. View at Publisher · View at Google Scholar · View at Scopus
  43. R. Mechoulam, D. Panikashvili, and E. Shohami, “Cannabinoids and brain injury: therapeutic implications,” Trends in Molecular Medicine, vol. 8, no. 2, pp. 58–61, 2002. View at Publisher · View at Google Scholar · View at Scopus
  44. B. F. Cravatt, D. K. Giang, S. P. Mayfield, D. L. Boger, R. A. Lerner, and N. B. Gilula, “Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides,” Nature, vol. 384, no. 6604, pp. 83–87, 1996. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Ouyang and X. Shen, “Critical role of ASK1 in the 6-hydroxydopamine-induced apoptosis in human neuroblastoma SH-SY5Y cells,” Journal of Neurochemistry, vol. 97, no. 1, pp. 234–244, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. M. Wilhelm, Z. Xu, N. V. Kukekov, S. Gire, and L. A. Greene, “Proapoptotic nix activates the JNK pathway by interacting with POSH and mediates death in a Parkinson disease model,” Journal of Biological Chemistry, vol. 282, no. 2, pp. 1288–1295, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. J. Rodriguez-Blanco, V. Martín, F. Herrera, G. García-Santos, I. Antolín, and C. Rodriguez, “Intracellular signaling pathways involved in post-mitotic dopaminergic PC12 cell death induced by 6-hydroxydopamine,” Journal of Neurochemistry, vol. 107, no. 1, pp. 127–140, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. G. Cohen and R. E. Heikkila, “The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6 hydroxydopamine, dialuric acid, and related cytotoxic agents,” Journal of Biological Chemistry, vol. 249, no. 8, pp. 2447–2452, 1974. View at Google Scholar · View at Scopus
  49. Y. Izumi, H. Sawada, N. Sakka et al., “p-quinone mediates 6-hydroxydopamine-induced dopaminergic neuronal death and ferrous iron accelerates the conversion of p-quinone into melanin extracellularly,” Journal of Neuroscience Research, vol. 79, no. 6, pp. 849–860, 2005. View at Publisher · View at Google Scholar · View at Scopus
  50. Y. Saito, K. Nishio, Y. Ogawa et al., “Molecular mechanisms of 6-hydroxydopamine-induced cytotoxicity in PC12 cells: involvement of hydrogen peroxide-dependent and -independent action,” Free Radical Biology and Medicine, vol. 42, no. 5, pp. 675–685, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. M. Bouaboula, C. Poinot-Chazel, B. Bourrié et al., “Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1,” Biochemical Journal, vol. 312, part 2, pp. 637–641, 1995. View at Google Scholar · View at Scopus
  52. M. G. Sánchez, L. Ruiz-Llorente, A. M. Sánchez, and I. Díaz-Laviada, “Activation of phosphoinositide 3-kinase/PKB pathway by CB1 and CB2 cannabinoid receptors expressed in prostate PC-3 cells. Involvement in Raf-1 stimulation and NGF induction,” Cellular Signalling, vol. 15, no. 9, pp. 851–859, 2003. View at Publisher · View at Google Scholar · View at Scopus
  53. D. N. Dhanasekaran and E. P. Reddy, “JNK signaling in apoptosis,” Oncogene, vol. 27, no. 48, pp. 6245–6251, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. S. Eminel, L. Roemer, V. Waetzig, and T. Herdegen, “c-Jun N-terminal kinases trigger both degeneration and neurite outgrowth in primary hippocampal and cortical neurons,” Journal of Neurochemistry, vol. 104, no. 4, pp. 957–969, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. X.-J. Qi, G. M. Wildey, and P. H. Howe, “Evidence that Ser87 of BimEL is phosphorylated by Akt and regulates BimEL apoptotic function,” Journal of Biological Chemistry, vol. 281, no. 2, pp. 813–823, 2006. View at Publisher · View at Google Scholar · View at Scopus
  56. G. V. Putcha, S. Le, S. Frank et al., “JNK-mediated BIM phosphorylation potentiates BAX-dependent apoptosis,” Neuron, vol. 38, no. 6, pp. 899–914, 2003. View at Publisher · View at Google Scholar · View at Scopus
  57. D. Rueda, I. Galve-Roperh, A. Haro, and M. Guzman, “The CB1 cannabinoid receptor is coupled to the activation of c-jun N-terminal kinase,” Molecular Pharmacology, vol. 58, no. 4, pp. 814–820, 2000. View at Google Scholar · View at Scopus
  58. E. J. Downer, M. P. Fogarty, and V. A. Campbell, “Tetrahydrocannabinol-induced neurotoxicity depends on CB1 receptor-mediated c-Jun N-terminal kinase activation in cultured cortical neurons,” British Journal of Pharmacology, vol. 140, no. 3, pp. 547–557, 2003. View at Publisher · View at Google Scholar · View at Scopus
  59. K. P. Sarker, K. K. Biswas, M. Yamakuchi et al., “ASK1-p38 MAPK/JNK signaling cascade mediates anandamide-induced PC12 cell death,” Journal of Neurochemistry, vol. 85, no. 1, pp. 50–61, 2003. View at Google Scholar · View at Scopus
  60. L. Ruiz, A. Miguel, and I. Díaz-Laviada, “Δ9-tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism,” FEBS Letters, vol. 458, no. 3, pp. 400–404, 1999. View at Publisher · View at Google Scholar · View at Scopus
  61. L. Velasco, L. Ruiz, M. G. Sánchez, and I. Díaz-Laviada, “Δ9-tetrahydrocannabinol increases nerve growth factor production by prostate PC-3 cells: involvement of CB1 cannabinoid receptor and Raf-1,” European Journal of Biochemistry, vol. 268, no. 3, pp. 531–535, 2001. View at Publisher · View at Google Scholar · View at Scopus